Clinical trials: Bladder
Overactive Bladder
Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence
A pre-market, prospective, non-randomized acute feasibility study for the treatment of patients with urinary incontinence (UI) as a consequence of urinary incontinence.
- Trial name
- NCT03643380
- Testing
- AHLeveeS System
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Neuspera Medical, Inc.
Superficial Bladder Cancer t1a
Skipping BCG for T1a Urinary Bladder Tumor.
Bladder cancer is the most common malignancy involving theurinary system and the ninth most common malignancy worldwide .In Egypt, the urinary bladder cancer accounted for about 31% of the total incidence of cancers that…
- Trial name
- NCT04298073
- Volunteers
- 43 people
- Sponsor
- Assiut University
Spinal Cord Injuries (SCI), Neurogenic Lower Urinary Tract Dysfunction
Radio-frequency (RF) Bladder Monitor
The goal of this pilot feasibility study is to evaluate a wearable microwave (MW)-based bladder monitoring system in adult volunteers and those with spinal cord injury (SCI) who use self-catheterization for bladder management.
- Conditions
- Spinal Cord Injuries (SCI), Neurogenic Lower Urinary Tract Dysfunction, Neurogenic Bladder (NB)
- Trial name
- NCT07639541
- Testing
- Wearable microwave Bladder Monitoring System
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Overactive Bladder Syndrome
Role of Combination Therapy in Women With Refractory Overactive Bladder
Defined by the International Continence Society (ICS) as urinary "urgency, with or without urge incontinence, usually with frequency and nocturia", overactive bladder (OAB) presents as challenging syndrome to treat.
- Trial name
- NCT06438861
- Testing
- Vibegron 75mg
- Sponsor
- University of Alabama at Birmingham
Urinary Incontinence
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder
This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
- Trial name
- NCT00127270
- Testing
- Darifenacin, Behavioral therapy
- Where
- 67 sites in United States
- Volunteers
- 395 people
- Sponsor
- Novartis
Hematuria - Cause Not Known
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
This study includes adult patients who see a urologist because of blood in their urine. The amount is so small it can only be seen with a microscope. This is called microhematuria. There can be many reasons for microhematuria.
- Trial name
- CREDIBLE (NCT06394869)
- Testing
- Cxbladder Triage Plus
- Where
- 20 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Pacific Edge Limited
Urinary Bladder Neoplasms
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.
- Trial name
- SunRISe-2 (NCT04658862)
- Testing
- Cetrelimab, TAR-200, Cisplatin
- Where
- 290 sites in United States, Argentina and 23 more
- Volunteers
- 518 people
- Sponsor
- Janssen Research & Development, LLC
Spinal Cord Injury
Electrical Control of Bladder in Spinal Cord Injury Patients
The investigators will continue their work with implanted stimulators to improve bladder and bowel function. Electrical stimulation produces simultaneous contraction of sphincters with the target organs, making emptying…
- Trial name
- NCT00011570
- Testing
- Bladder & Bowel Control
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- US Department of Veterans Affairs
Painful Bladder Syndrome, Interstitial Cystitis
Prospective Trial Comparing Intravesical Chondroitin Sulphate 2% and DMSO in the Treatment of PBS/Interstitial Cystitis
Painful bladder syndrome/interstitial cystitis (PBS/IC)is a disease of unknown origin with a significant impact on the quality of life.
- Trial name
- NCT04268810
- Testing
- Bladder instillations
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- National Multiple Sclerosis Center
Painful Bladder Syndrome, Interstitial Cystitis
Botox as a Treatment for Interstitial Cystitis in Women
Patients with interstitial cystitis have been well documented to have pelvic floor muscle tenderness as well as pain on bladder distension.
- Trial name
- NCT00194610
- Testing
- Botox, normal saline
- Volunteers
- 20 people
- Sponsor
- University of Washington
Bladder Cancer
Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
Gemcitabine and Cisplatin are standard chemotherapy drugs used to treat advanced urothelial cancer. There is no standard chemotherapy for patients who cannot receive Cisplatin.
- Trial name
- NCT01622660
- Testing
- Gemcitabine, Pazopanib
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
This is a Phase 3, open-label single-arm trial designed to evaluate the safety and efficacy of NDV-01 (sustained-release gemcitabine-docetaxel) in adult participants with NMIBC with CIS who have failed BCG therapy and who have…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
- Trial name
- RESCUE (NCT07342517)
- Testing
- NDV-01 (sustained-release gemcitabine-docetaxel)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Relmada Therapeutics, Inc.
Overactive Bladder, Stress Incontinence
Effects of Low-intensity Excoporeal Shock Wave Therapy (LiESWT) on Women With Pelvic Floor Dysfunction
1. This study needles female reproductive urinary tract, likely bladder hyperactivity, active urinary incontinence and interstitial cystitis, observation use of low-capacity seismic wave (LiESWT) therapy combined with combined…
- Conditions
- Overactive Bladder, Stress Incontinence, Interstitial Cystitis, Female Sexual Dysfunction
- Trial name
- NCT05337813
- Testing
- "Storz Medical" Extracoporeeal Shock Wave Therapy System
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
This phase I trial tests the safety and side effects of a PD-L1/IDO peptide vaccine (IO102-IO103) in combination with pembrolizumab in treating patients with non-muscle invasive bladder cancer.
- Conditions
- High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Trial name
- NCT05843448
- Testing
- PD-L1/IDO Peptide Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Davis
Urinary Tract Infection, Pyelonephritis
Risk Factors for Recurrent Urinary Tract Infection in Children
The purpose of this study is to determine clinical and urodynamic risk factors for recurrent urinary tract infection in 5-18 years old children.
- Conditions
- Urinary Tract Infection, Pyelonephritis, Cystitis
- Trial name
- NCT00528476
- Where
- Lithuania
- Volunteers
- 161 people
- Sponsor
- Kaunas University of Medicine
Bladder Cancer
The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease
The investigators hypothesize that circulating tumor cells (CTC) will be observed in patients with muscle-invasive or metastatic bladder cancer and that CTC will become undetectable, at least transiently, in a fraction of…
- Trial name
- NCT00829920
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Colorado, Denver
Overactive Bladder
A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)
The purpose of this study was to assess the efficacy of Hibero (Mirabegron) versus active control (Ditropan: Oxybutynin Chloride) in the treatment of pediatric subjects (5 to < 18 years of age) with overactive bladder.
- Trial name
- NCT06181591
- Testing
- Mirabegron 50 MG, Oxybutynin Chloride 5 MG
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Seoul National University Hospital
Overactive Bladder, Overactive Bladder Syndrome
OnabotulinumtoxinA Bladder Injection Study
Patients with overactive bladder (OAB) will be randomly assigned (like a flip of a coin) to receive 100 units of onabotulinumtoxinA injected into the bladder at either 3 sites or 10 sites.
- Conditions
- Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Incontinence
- Trial name
- NCT03523091
- Testing
- OnabotulinumtoxinA 100Unit Injection
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Corewell Health East
Urinary Bladder, Overactive
Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents
This single-dose study will investigate how well solifenacin suspension is taken up, how long it stays in the body and how well it will be tolerated in children and adolescents aged 5-17 years with symptoms of overactive bladder.
- Trial name
- NCT01262391
- Testing
- Solifenacin succinate suspension 2.5 mg, Solifenacin succinate suspension 5 mg, Solifenacin succinate suspension 10 mg
- Where
- 8 sites in Belgium, Denmark and 2 more
- Volunteers
- 42 people
- Sponsor
- Astellas Pharma Inc
Urinary Retention
Use of The Spanner Temporary Prostatic Stent as an Alternative to a Urinary Catheter to Achieve Bladder Drainage in Men
The Spanner is being evaluated for use to manage voiding dysfunction and lower urinary tract symptoms in subjects to achieve bladder drainage in men unfit for other treatments.
- Trial name
- NCT02643849
- Testing
- The Spanner Temporary Prostatic Stent
- Where
- 6 sites in United States
- Volunteers
- 107 people
- Sponsor
- SRS Medical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.